泰凌医药：预计1-10月录得公司拥有人应占亏损净额3500万元-3700万元

格隆汇2025-01-08

格隆汇1月8日丨泰凌医药(01011.HK)公布，集团预期于截至2024年10月31日止十个月将录得公司拥有人应占亏损净额介乎人民币3500万元至人民币3700万元，而截至2023年10月31日止十个月则录得亏损净额约人民币1.53亿元。期间预期亏损净额减少乃主要由于：(a)于该期间并无录得生产及销售中成药业务("出售业务"，该业务由公司前全资附属公司苏州第壹制药有限公司(已于2023年8月由集团...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2501745104?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-08 17:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2501745104","market":"hk","top_or_hot":-1,"title":"泰凌医药：预计1-10月录得公司拥有人应占亏损净额3500万元-3700万元","media":"格隆汇","content":"<div>\n<p>格隆汇1月8日丨泰凌医药(01011.HK)公布，集团预期于截至2024年10月31日止十个月将录得公司拥有人应占亏损净额介乎人民币3500万元至人民币3700万元，而截至2023年10月31日止十个月则录得亏损净额约人民币1.53亿元。期间预期亏损净额减少乃主要由于：(a)于该期间并无录得生产及销售中成药业务(\"出售业务\"，该业务由公司前全资附属公司苏州第壹制药有限公司(已于2023年8月由集团...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010817353995fcac4f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>泰凌医药：预计1-10月录得公司拥有人应占亏损净额3500万元-3700万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n泰凌医药：预计1-10月录得公司拥有人应占亏损净额3500万元-3700万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 17:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010817353995fcac4f&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇1月8日丨泰凌医药(01011.HK)公布，集团预期于截至2024年10月31日止十个月将录得公司拥有人应占亏损净额介乎人民币3500万元至人民币3700万元，而截至2023年10月31日止十个月则录得亏损净额约人民币1.53亿元。期间预期亏损净额减少乃主要由于：(a)于该期间并无录得生产及销售中成药业务(\"出售业务\"，该业务由公司前全资附属公司苏州第壹制药有限公司(已于2023年8月由集团...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010817353995fcac4f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010817353995fcac4f&s=b","article_id":"2501745104","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010817353995fcac4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501745104","pubTimestamp":1736328931,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇1月8日丨泰凌医药公布，集团预期于截至2024年10月31日止十个月将录得公司拥有人应占亏损净额介乎人民币3500万元至人民币3700万元，而截至2023年10月31日止十个月则录得亏损净额约人民币1.53亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","01011":"泰凌医药"},"translate_title":"NT Pharma: It is expected to record a net loss attributable to the company's owners of 35 million to 37 million yuan from January to October","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"格隆汇1月8日丨泰凌医药(01011.HK)公布，集团预期于截至2024年10月31日止十个月将录得公司拥有人应占亏损净额介乎人民币3500万元至人民币3700万元，而截至2023年10月31日止十个月则录得亏损净额约人民币1.53亿元。期间预期亏损净额减少乃主要由于：(a)于该期间并无录得生产及销售中成药业务(\"出售业务\"，该业务由公司前全资附属公司苏州第壹制药有限公司(已于2023年8月由集团出售)经营)亏损(上一期间：亏损约人民币1.10亿元)；及(b)本集团于上一期间就两名顾问为集团项目提供有关监督技术及产品注册、调研及开发、制定临床试验的研究计划，以及向监管机构提交临床申请的顾问服务所支付的一次性顾问费用人民币3770万元，而集团于该期间并无支付任何顾问费用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501745104","isCrawlerRequest":true}